TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Revenue ScalingExpanding
Percentile Rank67
3Y CAGR-8.6%
5Y CAGR+56.9%
Studio
Year-over-Year Change

Total revenue from sales of goods and services

3Y CAGR
-8.6%/yr
Annual compound
5Y CAGR
+56.9%/yr
Recent deceleration
Percentile
P67
Within normal range
vs 5Y Ago
9.5x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$10.32M+266.7%
2024$2.82M-86.6%
2023$21.05M+55.5%
2022$13.54M+33.5%
2021$10.14M+834.7%
2020$1.08M-
2019$0.00-